1. Home
  2. RNAZ vs CPHI Comparison

RNAZ vs CPHI Comparison

Compare RNAZ & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

HOLD

Current Price

$8.35

Market Cap

8.5M

Sector

Health Care

ML Signal

HOLD

Logo China Pharma Holdings Inc.

CPHI

China Pharma Holdings Inc.

N/A

Current Price

$1.74

Market Cap

9.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RNAZ
CPHI
Founded
2016
N/A
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5M
9.2M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
RNAZ
CPHI
Price
$8.35
$1.74
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$280.00
N/A
AVG Volume (30 Days)
9.2K
11.6K
Earning Date
11-14-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,052,266.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.15
$1.20
52 Week High
$468.44
$3.35

Technical Indicators

Market Signals
Indicator
RNAZ
CPHI
Relative Strength Index (RSI) 35.57 56.03
Support Level $8.20 $1.63
Resistance Level $9.00 $1.88
Average True Range (ATR) 0.43 0.10
MACD 0.06 0.02
Stochastic Oscillator 12.18 67.44

Price Performance

Historical Comparison
RNAZ
CPHI

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.

Share on Social Networks: